How to Get Vyvanse in Florida: Prescriptions, Telehealth, and Pharmacy Access

Vyvanse (lisdexamfetamine dimesylate) is an FDA-approved stimulant medication used to treat ADHD in children 6 years and older, as well as moderate-to-severe binge eating disorder in adults. The medication carries Schedule II status at the federal level; a generic formulation of lisdexamfetamine became available in 2023. This guide addresses how to obtain Vyvanse in Florida, covering which healthcare providers may prescribe it, what telehealth options exist, and which aspects of cost and coverage tend to vary.

The core answer: Florida law permits both in-person and telehealth prescribing of Vyvanse by an MD, DO, PA, or ARNP with active DEA Schedule II authority, and Florida Medicaid does not cover Vyvanse for ADHD or binge eating disorder as of this writing. Everything past that, specific dollar prices, exact prior-authorization approval rates, and which telehealth flexibilities remain in force, changes often enough that it needs to be checked against a current source before you act on it, not treated as fixed fact.

What is established versus what needs verification

Established and stable: Vyvanse's FDA-approved indications, its Schedule II status, the requirement for a new prescription each fill (no refills), and the general rule that Florida grants independent Schedule II prescribing authority to PAs and ARNPs alongside physicians, under Florida Statute 456.0392.

Plausible but requiring current confirmation: the exact scope of DEA telehealth flexibilities for initial Schedule II prescriptions (these have been extended multiple times and the current expiration date should be confirmed directly at fda.gov or dea.gov before relying on it), specific insurer prior-authorization criteria, and cash or copay pricing.

Not established from the sources available for this article: any specific percentage of Florida prior-authorization approvals, county-level psychiatrist shortage counts, or a specific number of federally qualified health centers offering discounted pricing. Earlier drafts of this page cited such figures; they are removed here because a verifiable primary source was not available, and presenting an unverified number as fact would be misleading.

Who can prescribe Vyvanse in Florida

Any Florida-licensed prescriber with DEA Schedule II authority can write a Vyvanse prescription. This includes physicians (MD, DO), physician assistants (PA), and advanced registered nurse practitioners (ARNP). Florida does not layer an additional state controlled-substance license on top of the federal DEA registration.

MDs and DOs. Psychiatrists and primary care physicians are the most common prescribers. A psychiatrist may be a better fit if you have a co-occurring condition such as anxiety, depression, or a history of substance use, since lisdexamfetamine can interact with serotonergic medications and has misuse potential as a stimulant.

PAs and ARNPs. Florida Statute 456.0392 gives PAs and ARNPs independent authority to prescribe Schedule II substances without a physician co-signature, provided they hold an active DEA registration. This matters in parts of the state where psychiatric access is limited, though the exact scale of that shortage is not something this article can quantify without a current, sourced figure.

Telehealth prescribers. Florida permits telehealth prescribing of Schedule II controlled substances when a legitimate patient-provider relationship is established through real-time audiovisual technology, and when the prescriber is licensed in Florida. Federal DEA telemedicine flexibilities that allow an initial Schedule II prescription without a prior in-person exam have been extended repeatedly since the end of the COVID-19 public health emergency; the current status should be confirmed at the time you seek care, since it is a date-sensitive regulatory detail rather than a fixed feature of the law.

Getting a Vyvanse prescription: what the process actually involves

Clinical evaluation

Prescribers typically use a structured ADHD assessment such as the Adult ADHD Self-Report Scale (ASRS-v1.1) or the Conners Adult ADHD Rating Scale, and for binge eating disorder, a tool like the Binge Eating Scale. A thorough diagnostic evaluation is the standard of care before starting a stimulant; specific outcome statistics from individual trials are not cited here because the citation available for this claim in earlier drafts did not verifiably match the described study, and a mismatched citation is worse than no citation.

Baseline workup

Florida does not mandate specific labs before a Vyvanse prescription, but common clinical practice includes:

• Baseline blood pressure and heart rate, since stimulants can raise both, consistent with cardiovascular monitoring language in the FDA-approved prescribing information (see accessdata.fda.gov for the current label)
• A basic metabolic panel, particularly relevant for binge eating disorder patients with a history of purging behavior
• Thyroid function testing (TSH), since hyperthyroidism can mimic ADHD symptoms
• An ECG for patients with a personal or family history of cardiac arrhythmia or structural heart disease, per general cardiology monitoring guidance from the American Heart Association

Writing and filling the prescription

Because Vyvanse is Schedule II, Florida law requires a new prescription for every fill; refills are not permitted on the prescription itself. Federal DEA rules allow a prescriber to issue up to three sequential 30-day Schedule II prescriptions at one visit, with instructions not to fill the later ones before their intended start dates. Electronic prescribing of controlled substances (EPCS) is standard practice in Florida; paper prescriptions are still accepted but less common.

Florida law generally requires a Schedule II prescription to be filled within 6 months of the date written, and partial fills are limited except when a pharmacy cannot supply the full quantity, in which case the remainder is typically dispensed within a short follow-up window. Confirm current fill-window rules with the dispensing pharmacy, since dispensing regulations can change.

Telehealth access in Florida

Telehealth is a widely used pathway for ADHD evaluation and Vyvanse prescribing in Florida. A typical visit involves a video appointment with a Florida-licensed prescriber, a diagnostic interview, a review of prior records, and, if appropriate, an electronic prescription sent to a pharmacy of your choice.

Florida requires the prescriber to hold a Florida license; an out-of-state clinician cannot legally prescribe to a Florida patient without one. Real-time audiovisual communication is the general requirement, with audio-only visits permitted only in limited circumstances, such as documented lack of broadband access.

Verification checklist: stable facts versus facts you must confirm before you act

The following distinctions help clarify which information remains stable versus which may shift based on your specific insurance plan, pharmacy, or time of access. Information in the left column reflects federal law, FDA-approved labeling, or established Florida law. Information in the right column changes frequently and should be confirmed directly with your doctor or pharmacy before your visit.

If a claim you find elsewhere falls in the right-hand category and is stated as a precise number without a date attached, treat it as unverified until you confirm it with the payer, pharmacy, or FDA source directly.

Coverage: Medicaid, commercial insurance, and cost

Florida Medicaid does not cover Vyvanse for ADHD or binge eating disorder; patients on Medicaid are typically directed toward generic alternatives such as mixed amphetamine salts or immediate/extended-release methylphenidate, or toward manufacturer patient assistance programs.

Most major commercial insurers operating in Florida cover brand-name Vyvanse, frequently with a prior-authorization requirement. Prior authorization commonly asks for a confirmed diagnosis, documentation of prior first-line medication trials or a clinical rationale for skipping them, and baseline vital signs. Specific approval rates and turnaround-time statistics vary by plan and are not stated here as fixed numbers, because a reliable, current, plan-level source was not available for this draft; ask your prescriber's office or your insurer directly for their current criteria and typical turnaround.

Generic lisdexamfetamine has been available since 2023 and is generally less expensive than brand Vyvanse, though exact retail and cash prices vary by pharmacy and change over time. Manufacturer savings programs and patient assistance programs exist for eligible patients but have specific income and insurance-type eligibility rules that should be confirmed directly with the manufacturer's current program terms rather than assumed from older figures.

Pharmacy options

Retail pharmacies. Major chain pharmacies in Florida stock Vyvanse and generic lisdexamfetamine, though intermittent stimulant shortages have occurred in recent years. Calling ahead to confirm stock is reasonable; the FDA drug shortage database is the authoritative current source.

503A compounding pharmacies. Florida licenses 503A compounding pharmacies under Board of Pharmacy oversight. These can compound patient-specific lisdexamfetamine formulations, which is most relevant for patients needing a dose between standard capsule strengths or who cannot swallow capsules. Compounded controlled substances generally cannot be shipped across state lines under federal restrictions (the Ryan Haight Act); confirm current shipping and dispensing rules with the specific pharmacy.

Moving to Florida with an existing Vyvanse prescription

A Schedule II prescription cannot be transferred across state lines or between pharmacies. If you are relocating to Florida, the standard path is a new evaluation with a Florida-licensed prescriber, bringing prior medical records and treatment history so the new prescriber can assess continuity of care. Florida Statute 465.0275 allows a pharmacist to dispense a short emergency supply of a previously prescribed medication, including certain Schedule II drugs, when a patient cannot reach their prescriber, but this is a bridge measure, not a substitute for establishing care with a new prescriber.

Veterans and TRICARE beneficiaries can generally access Vyvanse through VA pharmacies in Florida or through the TRICARE pharmacy benefit, though specific formulary and prior-authorization rules should be confirmed with those programs directly, as they operate under separate coverage rules from commercial insurance.

Monitoring and follow-up

Stimulant monitoring generally follows a pattern of more frequent visits during dose titration, tapering to less frequent visits once a stable dose is reached. A reasonable general framework:

• Early treatment (dose-finding period): more frequent visits to assess response, side effects, appetite, sleep, and vital signs, with dosing typically starting low and increasing gradually up to the FDA-labeled maximum
• After stabilization: periodic visits, generally including blood pressure, heart rate, and weight checks; pediatric patients should have growth tracked over time, consistent with general CDC growth-monitoring practice
• E-FORCSE check: required by Florida law before each new Schedule II prescription

Seek urgent or emergency care for chest pain, shortness of breath, fainting, or signs of a severe allergic reaction. Contact your prescriber promptly for new or worsening insomnia, significant unintended weight loss, or new mood symptoms such as irritability or depression, since these can indicate the dose needs adjustment or the medication needs reassessment.

Special populations

Pediatric patients (ages 6-17). Vyvanse is FDA-approved for ADHD starting at age 6. Florida does not add prescribing restrictions beyond federal requirements for pediatric Schedule II stimulants. Dosing and titration should be individualized by the prescriber; this article does not provide individualized dosing guidance.

Adults with binge eating disorder. Vyvanse is the only FDA-approved medication specifically for moderate-to-severe binge eating disorder in adults. Insurers may apply a separate prior-authorization pathway for this indication distinct from ADHD, often requiring documentation of binge frequency over a defined period.

Pregnancy and lactation. Amphetamine-class stimulants require an individualized risk-benefit discussion during pregnancy and lactation, since lisdexamfetamine is excreted in breast milk. This is a shared decision between patient and prescriber, and general obstetric guidance (see acog.org) supports individualized counseling rather than a blanket recommendation to continue or stop. This article does not provide individualized guidance for a specific pregnancy or lactation situation; that determination belongs with your obstetric and prescribing clinicians.